Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ivantis, Inc.
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive